4599
StemRim
2026/07/13
StemRim announced the registration of a patent in Canada for Ledasemide, aiming to expand its application to cardiomyopathy and heart failure. Since March 2024, a Phase II physician-led clinical trial has been initiated with Osaka University Graduate School of Medicine.
